Skip to content
About Us
Menu Toggle
Overview
Leadership Team
Board of Directors
Pipeline
Menu Toggle
Overview
Targeted Oncology Programs
Resources
Investors
Menu Toggle
Corporate Profile
Press Releases
Events & Presentations
Stock Information
Financial Filings
Corporate Governance
Investor Resources
Working at Ikena
Menu Toggle
Overview
Career Opportunities
Contact
Main Menu
IK-930, a TEAD Paralog Selective Inhibitor for Treating YAP/TAZ-TEAD Dependent Cancers
←
Previous Sci. Publications
Next Sci. Publications
→
About Us
Menu Toggle
Overview
Leadership Team
Board of Directors
Pipeline
Menu Toggle
Overview
Targeted Oncology Programs
Resources
Investors
Menu Toggle
Corporate Profile
Press Releases
Events & Presentations
Stock Information
Financial Filings
Corporate Governance
Investor Resources
Working at Ikena
Menu Toggle
Overview
Career Opportunities
Contact
About Us
Menu Toggle
Overview
Leadership Team
Board of Directors
Pipeline
Menu Toggle
Overview
Targeted Oncology Programs
Resources
Investors
Menu Toggle
Corporate Profile
Press Releases
Events & Presentations
Stock Information
Financial Filings
Corporate Governance
Investor Resources
Working at Ikena
Menu Toggle
Overview
Career Opportunities
Contact
Scroll to Top
Ikena has merged with ImageneBio
Visit ImageneBio for more information
Click here to visit our Investor Relations page
